Ligand Pharmaceutical (LGND) Stock
Biotech firm providing drug development technology and earning royalties. Here's the price, business snapshot, and what's worth knowing about Ligand Pharmaceutical in June 2026.
Ligand Pharmaceuticals (LGND) is a US-based biotechnology company that provides technologies and services to help other drug developers discover, develop and commercialise medicines. Instead of focusing mainly on its own drug pipeline, Ligand earns revenue through licensing, milestone payments, royalties and strategic collaborations tied to partner programmes. Its portfolio includes platform technologies such as Captisol (drug formulation) and OmniAb (antibody discovery), which can broaden the company’s exposure across therapeutic areas. With a market capitalisation of about $3.66 billion, Ligand offers a royalty-driven business model that can deliver recurring revenues, but it remains dependent on partner success, regulatory approvals and licensing activity. Investors should be aware that biotech stocks are typically volatile; past performance does not predict future returns. This is general, educational information and not personal investment advice — suitability depends on your circumstances and risk tolerance, so consider professional advice before making decisions.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Ligand Pharmaceuticals stock, expecting its price to rise significantly.
Financial Health
Ligand Pharmaceuticals is generating strong revenue and cash flow, reflecting a healthy financial position.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
ACADIA PHARMACEUTICALS INC
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ADAPTIVE BIOTECHNOLOGIES CORP
Adaptive Biotechnologies Corporation is a commercial-stage company. The Company focuses on the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform applies its technologies to read the genetic code of a patient's immune system. It operates through two segments, which include Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic testing service, offered to clinicians. Its Immune Medicine business focuses on immune-repertoire sequencing, target antigen discovery, data licensing and TCR-antigen prediction models in the identification, validation, development and adoption of products and services.
ABCELLERA BIOLOGICS INC
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
Baskets Featuring LGND
LNP Patent Holders Shape Drug Delivery Value 2025
The massive settlement between Moderna and Arbutus/Genevant highlights the critical value of the lipid nanoparticle (LNP) technology used in mRNA vaccines. This creates a potential investment opportunity in companies that hold key patents for drug delivery systems, as they may be poised for lucrative licensing deals or acquisitions.
Published: 4 March 2026
Explore BasketSanofi Dupixent Success Overview | Pharma Investment
Sanofi's recent profit surge, driven by its blockbuster drug Dupixent, highlights a powerful investment theme. This idea focuses on innovative pharmaceutical companies with high-growth drugs and the broader ecosystem that supports their success.
Published: 24 October 2025
Explore BasketPharma M&A Targets: Biotech Stocks to Watch 2025
AbbVie is spending $2.7 billion on external R&D, highlighting a major industry trend of large pharmaceutical companies acquiring innovation. This creates a potential opportunity among the smaller biotech firms that are becoming prime acquisition targets.
Published: 5 October 2025
Explore BasketNavigating Pharma Price Controls
President Trump's ultimatum to major pharmaceutical firms to lower drug prices creates significant market uncertainty for brand-name drug makers. This situation could benefit companies that thrive on reducing healthcare costs, such as generic drug manufacturers and prescription discount platforms.
Published: 4 August 2025
Explore BasketWhy You’ll Want to Watch This Stock
Royalty Revenue Model
Recurring royalties and milestone payments can provide revenue visibility, though those streams depend on partner successes and are vulnerable to setbacks.
Proprietary Technology Platforms
Platforms such as Captisol and OmniAb can attract partners and diversify exposure, but they require ongoing investment and commercial uptake to deliver value.
Extensive Partnership Exposure
A wide partner base spreads risk across programmes and indications, yet regulatory delays or clinical failures at partners can still materially affect results.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
